(UPDATE) Ixazomib (Ninlaro)
Carfilzomib
(UPDATE) Daratumumab (MM)
Elotuzumab
NCCN Guidelines for Patients: Multiple Myeloma
Multiple Myeloma Research Foundation (MMRF)
ASCO: COVID-19 Medical Resources
NCCN Virtual Reimbursement Resource Room